Tag #Stock Market

Showing 145 to 156 of 1,561 results

cincodias.elpais.com
🌐 75% Global Worthiness
News related image

Major Sportswear Brands Struggle Amidst Fitness Boom

Major sportswear brands like Nike and Puma are experiencing stock market declines due to decreased sales and profit margins in a post-pandemic market, despite a surge in global fitness; Adidas is an exception due to product innovation and disciplined management.

Progress

56% Bias Score

Decent Work and Economic Growth
cincodias.elpais.com
🌐 75% Global Worthiness
News related image

Grifols Stock Soars After Rejecting Brookfield Takeover Bid

Grifols' stock price jumped 8.99% to €13.51 after announcing its return to dividend payments and improved 2025 cash flow guidance, exceeding Brookfield's rejected €6.45 billion takeover bid from November 2024 by €1.85 billion in market capitalization.

Progress

40% Bias Score

Decent Work and Economic Growth
theglobeandmail.com
🌐 85% Global Worthiness
News related image

U.S.-EU Trade Deal Stalls European Stock Rally

A new U.S.-EU trade deal, involving a 15% tariff on most EU goods, has stalled a recent rally in European stocks, while U.S. stocks continue to reach new highs due to optimism around trade, AI, and potential interest rate cuts. The euro is also expected to fall for the first time this year.

Progress

40% Bias Score

Decent Work and Economic Growth
telegraaf.nl
🌐 75% Global Worthiness
News related image

AEX Index Sees Mixed Results: Philips Soars, Basic-Fit Plunges

The AEX index experienced a slight increase, with Philips soaring 8.5% due to improved profit forecasts, while Basic-Fit plummeted 12.5% due to rising costs; other companies showed mixed results.

Progress

32% Bias Score

Decent Work and Economic Growth
theglobeandmail.com
🌐 75% Global Worthiness
News related image

TSX Consumer Defensive Stocks: Valuations and Market Outlook

Analysis of the top 10 TSX consumer defensive stocks reveals valuations generally within ±10 percent of current market prices, despite some showing over 20 percent growth in the last year, while market indicators suggest potential overvaluation.

Progress

44% Bias Score

Reduced Inequality
forbes.com
🌐 75% Global Worthiness
News related image

Intel Stock Stagnates Amidst Revenue Decline and Foundry Challenges

Intel's stock price has risen only 2% this year, despite a $50 billion investment in its foundry business, as revenue has fallen from $79 billion in 2021 to a projected $52 billion in 2025 due to shrinking relevance in the CPU market and underwhelming foundry progress, while competitors AMD and Nvid...

Progress

56% Bias Score

Decent Work and Economic Growth
forbes.com
🌐 75% Global Worthiness
News related image

Chevron's Q2 Earnings: Expected Decline Amidst Weakening Demand

Chevron Corporation is expected to report a significant decrease in Q2 2024 earnings and revenue, with analysts forecasting EPS of $2.15 and revenue of $48.39 billion, representing a 29% and 9% decline, respectively, compared to the same period last year; however, the company maintains its capital e...

Progress

52% Bias Score

Decent Work and Economic Growth
cincodias.elpais.com
🌐 85% Global Worthiness
News related image

US Stock Market Gains Despite Tariff Risks

Positive US corporate earnings and favorable trade agreements, including a recent US-EU deal, are boosting US stock market performance, with indices like the S&P 500 showing significant gains despite the looming threat of tariffs.

Progress

44% Bias Score

Decent Work and Economic Growth
theguardian.com
🌐 85% Global Worthiness
News related image

AstraZeneca's US Focus Raises Concerns About UK Commitment

AstraZeneca CEO Pascal Soriot's recent comments praising the US pharmaceutical market and his silence on a potential US stock market listing raise concerns about the company's commitment to the UK, highlighting funding disparities and potential relocation costs.

Progress

52% Bias Score

Industry, Innovation, and Infrastructure
forbes.com
🌐 75% Global Worthiness
News related image

Sarepta Stock Surges After FDA Lifts Hold on Elevidys

Following the FDA's decision to lift the clinical hold on its Elevidys drug, Sarepta Therapeutics' stock price rose to approximately $19 in extended trading, driven by increased revenue potential and a company restructuring plan aiming for $400 million in annual cost savings by 2026.

Progress

44% Bias Score

Good Health and Well-being
forbes.com
🌐 75% Global Worthiness
News related image

MGM Resorts Q2 Earnings: Projected Decline Amidst Long-Term Growth Strategy

MGM Resorts' Q2 2025 earnings announcement, projected for July 30th, anticipates $0.55 EPS on $4.31B revenue, showing an 8% year-over-year earnings decline and stagnant revenue growth compared to last year's $0.60 EPS and $4.33B revenue; historically, the stock has declined 70% of the time post-earn...

Progress

48% Bias Score

Decent Work and Economic Growth
npr.org
🌐 85% Global Worthiness
News related image

US Stock Market Surges Despite Tariff Threats

Despite President Trump's tariff threats, the U.S. stock market is surging due to positive economic data (4.1% unemployment, better-than-expected corporate earnings), although some investors remain cautious about future trade deals with major partners like Canada, Mexico, and China.

Progress

44% Bias Score

Decent Work and Economic Growth

Showing 145 to 156 of 1,561 results